CSIMarket
 
Ocuphire Pharma Inc   (OCUP)
Other Ticker:  
 
 
Price: $2.6400 $0.11 4.348%
Day's High: $2.64 Week Perf: 7.76 %
Day's Low: $ 2.53 30 Day Perf: -2.94 %
Volume (M): 223 52 Wk High: $ 6.60
Volume (M$): $ 588 52 Wk Avg: $3.70
Open: $2.53 52 Wk Low: $2.34



 Market Capitalization (Millions $) 59
 Shares Outstanding (Millions) 22
 Employees -
 Revenues (TTM) (Millions $) 57
 Net Income (TTM) (Millions $) 29
 Cash Flow (TTM) (Millions $) 29
 Capital Exp. (TTM) (Millions $) 0

Ocuphire Pharma Inc
Ocuphire Pharma Inc is a pharmaceutical company that specializes in developing and commercializing novel therapies for the treatment of various eye disorders. The company focuses on addressing unmet medical needs and providing innovative therapies to improve the lives of patients with ophthalmic conditions. Ocuphire Pharma is committed to advancing eye care through its research, development, and commercialization efforts.


   Company Address: 37000 Grand River Avenue, Suite 120 Farmington Hills 48335 MI
   Company Phone Number: 957-9024   Stock Exchange / Ticker: NASDAQ OCUP
   OCUP is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Ocuphire Pharma Grants Inducement Awards to Top Executives Under Nasdaq Listing Rule 5635(c)(4)

Published Thu, Feb 15 2024 9:10 PM UTC

In an exciting development, Ocuphire Pharma, a leading clinical-stage ophthalmic biopharmaceutical company, has announced the approval of equity awards for two key executives. These inducement grants, issued under Nasdaq Listing Rule 5635(c)(4), reaffirm the company's commitment to attracting top talent and driving innovation in the field of retinal and refractive eye disord...

Clinical Study

Illuminating Advancements in the Treatment of Decreased Visual Acuity Under Dim Light: Ocuphire Pharma's Phentolamine Ophthalmic Solution Sheds New Light on Ophthalmology

Published Thu, Jan 4 2024 1:00 PM UTC

In the field of ophthalmology, significant strides have been made in understanding and treating various visual impairments. However, one specific condition that has posed challenges for both patients and healthcare professionals is decreased visual acuity under dim (mesopic) light conditions. Recognizing this unmet medical need, Ocuphire Pharma has received FDA agreement und...

Shares

Ocuphire Pharma Accelerates Growth with Inducement Grant to New COO

Published Mon, Nov 27 2023 9:38 PM UTC



Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company, has recently made an important announcement regarding an equity award granted to its newly appointed Chief Operating Officer (COO), Joseph K. Schachle. The grant was made under Ocuphire's 2021 Inducement Plan and has significant implications for the company's future growth and development. This...

Ocuphire Pharma Inc

Ocuphire Pharma Inc. Records Impressive Revenue of $3.674 Million in Q2 of 2023

Ocuphire Pharma Inc, a leading pharmaceutical company, has reported its financial results for the second quarter of 2023. The company generated $3.674 million in revenue during this period, indicating a positive growth trajectory. However, Ocuphire Pharma also recorded a net shortfall of $-4.961 million, which was slightly larger than the $-4.927 million shortfall experienced in the same quarter last year. This suggests that the company still faces financial challenges and needs to address its expenses.
Investors and analysts are eagerly waiting for the next financial update from Ocuphire Pharma Inc, which is scheduled to be released on November 03, 2023. This report is expected to provide a clearer picture of the company's financial position and indicate any improvements or concerns.

Ocuphire Pharma Inc

Ocuphire Pharma Inc Reports $1.749 Million in Q1 2023 Revenue, Showing Solid Financial Progress Amidst $5.791 Million Net Deficit

As a journalist analyzing the financial results of Ocuphire Pharma Inc, I can report that the company has disclosed a revenue of $1.749 million in the first quarter of 2023. This is good news for the company as it indicates that they are generating revenue and sustaining their operations.
However, the net deficit reported by Ocuphire Pharma Inc for the same period was $-5.791 million. This is a slight improvement from the $-6.595 million deficit reported in the first quarter of the previous year. Although the company is still operating at a loss, the decrease in deficit is a positive sign and can be attributed to several factors such as cost-cutting measures and improved revenue streams.






 

Ocuphire Pharma Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com